Hypothesis

Gut enterochromaffin (EC) cell‑derived serotonin (5‑HT) activates vagal afferents that potentiate slow‑wave sleep (SWS) drive, thereby enhancing glymphatic CSF‑interstitial fluid exchange and nocturnal clearance of metabolic waste. Age‑related decline in EC cell 5‑HT output reduces this vagal‑hypothalamic signal, fragmenting SWS and diminishing glymphatic flux, which contributes to the accumulation of neurotoxic aggregates seen in aging and neurodegeneration.

Mechanistic Rationale

1. EC cells release 5‑HT in response to mechanical and chemical cues from the gut lumen via Piezo2‑mediated mechanotransduction[5][6].
2. Peripheral 5‑HT cannot cross the BBB but activates 5‑HT2C and 5‑HT3 receptors on vagal afferents, increasing their firing rate to the nucleus tractus solitarius (NTS)[3][4].
3. NTS projects to the hypothalamic sleep‑regulatory centers – the ventrolateral preoptic area (VLPO) and the suprachiasmatic nucleus (SCN) – promoting GABAergic sleep‑onset and stabilizing SWS[2][7].
4. Robust SWS drives large‑amplitude slow oscillations that coordinate arterial pulsation‑driven glymphatic influx, facilitating clearance of Aβ, tau, and lactate[1].
5. With aging, microbiota diversity falls and EC cell 5‑HT synthesis declines[2], weakening vagal tone, fragmenting SWS, and lowering glymphatic efficiency.

Novel Predictions

• Selective chemogenetic activation of EC cell 5‑HT release in aged mice will restore vagal afferent firing, increase SWS delta power, and boost glymphatic tracer influx comparable to young controls.
• Conversely, vagotomy or 5‑HT2C antagonism in young mice will fragment SWS and reduce glymphatic clearance despite intact EC cell output.
• Longitudinal sampling of fecal SCFA, plasma 5‑HT, and EEG SW power in humans will show that lower gut‑derived 5‑HT predicts reduced SW amplitude and higher CSF amyloid‑β levels over 12 months.

Experimental Approach

Animal model – Use TPH1‑flox mice crossed with Villin‑CreERT2 for inducible EC‑specific 5‑HT knockdown; include a Cre‑dependent hM3Dq DREADD for chemogenetic activation. Readouts –

• In vivo vagal afferent electrophysiology (NTS) during light/dark cycles.
• EEG/EMG to quantify SWS duration, delta power, and spindle density.
• Glymphatic function measured by intrathecal injection of fluorescently labeled CSF‑tracer (e.g., Alexa‑647‑OVA) and two‑photon imaging of cortical interstitial clearance.
• Behavioral assays (novel object recognition, Morris water maze) to link clearance to cognition. Human correlative study – Collect stool for 16S rRNA sequencing, plasma for serotonin, and perform high‑density overnight EEG; subset undergo CSF amyloid‑β ELISA after lumbar puncture.

Potential Implications

If validated, the hypothesis positions the gut‑EC‑5‑HT‑vagal axis as a upstream regulator of the brain’s nightly "autopsy," suggesting that dietary prebiotics, probiotics, or targeted EC‑cell agonists could rescue SWS‑dependent clearance and delay age‑related cognitive decline. It also shifts the focus of insomnia therapies from purely central agents to peripheral serotonergic modulation.